Dean S. Woodman
Dean S. Woodman was elected Chairman of SciClone's Board of Directors in February 2004 and has been a Director since August 2000. Mr. Woodman was an investment banker for over four decades. From July 1989 to June 1999, he was a Managing Director of Furman Selz, an investment banking firm acquired in 1999 by ING Barings L.L.C. Mr. Woodman was a Managing Director in the investment banking group of Hambrecht & Quist (now JPMorgan Chase) from October 1984 to March 1988. He was a founding partner of Robertson Colman Stephens & Woodman, an investment banking firm, in 1978, and of Woodman Kirkpartrick & Gilbreath, an investment banking firm, in 1982. Mr. Woodman worked in the investment banking division of Merrill Lynch for 23 years where he spent 16 years as director of West Coast corporate finance until 1978. He is currently a director of MarineMax, Inc.
back to top


John D. Baxter, M.D.
John D. Baxter, M.D., has been a Director and the Chairman of our Scientific Advisory Board since June 1991.  Dr. Baxter is a senor member of the Methodist Hospital Research Institute, Houston , Texas .  He was associated with the University of California , San Francisco between 1970 and 2008.  He was Professor of Medicine from 1979 through 2008, Chief o f the Endocrinology Section, Parnassus Campus from 1980 to 1997, and Director of UCSF's Metabolic Research Unit from 1981 to 1999.  Dr. Baxter was President of The Endrocrine Society from June 2002 to June 2003.  Dr. Baxter was a founder and served as a director of California Biotechnology, Inc. (now Scios, Inc., a division of Johnson & Johnson) from 1982 until 1992 and was a founder and Director of Karo Bio A.B., a Swedish biotechnology company.  Dr. Baxter has been elected to the National Academy of Sciences and the Institute of Medicine of the National Academy of Sciences.
back to top

Friedhelm Blobel, Ph.D.
Friedhelm Blobel, Ph.D., has been our President, Chief Executive Officer and a Director since June 2, 2006. Before joining the Company, Dr. Blobel served most recently as President, Chief Executive Officer and a Director of Gryphon Therapeutics, Inc., a South San Francisco based biopharmaceutical company. Prior to joining Gryphon in July 2000, Dr. Blobel spent more than 20 years as an executive with the Hoechst Group and the Boehringer Mannheim Group, including many responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions, Chief Technology Officer, General Manager of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals (now Astellas) in Tokyo, Japan, Senior Vice President of Research & Development Diabetes and Patient Care in Mannheim, Germany as well as in Indianapolis, Indiana. Dr. Blobel earned his doctorate degree (“Dr.rer.nat.”; a Ph.D. equivalent) with a dissertation in Biochemistry and Microbiology from the University of Hohenheim, Germany and holds an advanced degree in Chemistry from the University of Stuttgart, Germany. He serves as a Director of Pelikan Technologies, Inc., a Palo Alto based private Biotech company.


Richard J. Hawkins
Richard J. Hawkins has been a Director since October 2004. Currently, Mr. Hawkins serves as the Chairman and CEO of LabNow, Inc., a privately-held company he founded in September 2003. LabNow is developing lab-on-a-chip sensor technology to be used in point-of-care diagnostic testing systems, including CD4 and viral load tests in resource scarce environments. From 1992 to 2000, Mr. Hawkins co-founded and served as Chairman of Sensus Drug Development, which developed and received regulatory approval for SOMAVERT®, a growth hormone antagonist approved for the treatment of acromegaly and now marketed by Pfizer in both the United States and Europe. In 1982, Mr. Hawkins founded Pharmaco, a clinical research organization (CRO) that in 1991 was merged with the predecessor of PPD-Pharmaco, becoming the cornerstone of one of the largest CROs in the world today. Mr. Hawkins graduated cum laude with a B.S. in Biology from Ohio University.
back to top

Rolf H. Henel
Rolf H. Henel has been a Director since June 1997. Mr. Henel has been a partner of Naimark & Associates, consultants to the health care industry, since 1994. Mr. Henel was a director and Treasurer of Bergen Community Blood Services from 1999 to 2005, Chairman of its Foundation from 2001 to 2004, and is the President of the Northern New Jersey Chapter of the American Association of Individual Investors. From 1978 to 1993, Mr. Henel was with American Cyanamid Company, most recently as President of Cyanamid International, Lederle Division. Mr. Henel was a director and Chief Operating Officer of Immunomedics, Inc. from 1996 to 1997. Mr. Henel holds a M.B.A. from New York University and a B.A. from Yale University. Mr. Henel is also a director of Penwest Pharmaceuticals Co., a pharmaceutical company, and Draxis Health Inc., a pharmaceutical company.
back to top

Ira D. Lawrence, M.D.
Ira D. Lawrence, M.D., has been a Director since June 2005.  Dr. Lawrence is currently employed by Medicis Pharmaceuticals of Scottsdale, AZ as Senior Vice President of Research and Development.  From June 2005 until May 2006, Dr. Lawrence served as President and Chief Executive Officer of SciClone Pharmaceuticals, Inc.  From 1995 to 2005, Dr. Lawrence was at Fujisawa Healthcare, Inc., most recently as Senior Vice President of Research and Development.  Fujisawa Healthcare, Inc. was the subsidiary of Fujisawa Pharmaceutical Co. that recently merged with Yamanouchi Pharmaceutical Co. to form Astellas Pharma Inc.  From 1993 to 1995, Dr. Lawrence served as Vice President of Research and Development at GenDerm Corporation.  Dr. Lawrence was the Associate Director of Clinical Studies, Immunology at Fujisawa Healthcare, Inc. from 1991 to 1993.  Prior to 1001, Dr. Lawrence practiced internal medicine and allergy/clinical immunology, most recently as the Assistant Chief of Staff at the Veterans Administration Lakeside Medical Center and Assistant Professor at Northwestern University Medical School .  Dr. Lawrence earned his M.D. degree, from the Hahnemann Medical College (now Drexel University College of Medicine) and his B.A. from Temple University .  Dr. Lawrence completed his internship and residency in internal medicine at Northwestern University and his fellowship at the Division of Allergy and Clinical Immunology at the Johns Hopkins University School of Medicine.
back to top

Jon S. Saxe
Jon S. Saxe, has been a Director since August 2000.  Mr. Saxe was President of PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) from 1995 to early-1999, and currently serves as a director of the company.  From mid-1993 to 1995, Mr. Saxe was President of Saxe Associates, Inc., consultants to venture capital firms and biotechnology, diagnostic, and pharmaceutical companies.  He was the President and CEO of Synergen, Inc. a biotechnology company, from 1989 to 1993.  Mr. Saxe is former Vice President, Licensing and Corporate Development and Head of Patent Law for Hoffmann-LaRoche Inc., where he worked for close to 30 years (1960-1989).  Mr. Saxe received his J.D. from George Washington University School of Law and his LL.M. from New York University School of Law.  He serves as a director of other public and private companies, including Durect Corporation, Sciele Pharma Corporation, InSite Vision and PDL BioPharma, Inc.  Mr. Saxe is also chairman of Entelos, Inc., a company listed on AIM in the UK , but is not a United States reporting company.
back to top